CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • BPTH Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit
  • 8-K Filing

Bio-Path (BPTH) 8-KBio-Path Holdings Reports Third Quarter 2021 Financial Results

Filed: 12 Nov 21, 7:10am
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 8-K Current report
    • 99.1 Bio-Path Holdings Reports Third Quarter 2021 Financial Results
    • Download Excel data file
    • View Excel data file
    BPTH similar filings
    • 29 Dec 21 Submission of Matters to a Vote of Security Holders
    • 17 Dec 21 Other Events
    • 13 Dec 21 Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting
    • 12 Nov 21 Bio-Path Holdings Reports Third Quarter 2021 Financial Results
    • 4 Nov 21 Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting
    • 27 Oct 21 Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors
    • 24 Aug 21 Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
    Filing view
    Share this filing

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT PURSUANT

    TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

    ​

    Date of report (Date of earliest event reported): November 12, 2021

    ​

    BIO-PATH HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

    ​

    ​

    ​

    Delaware

        

    001-36333

        

    87-0652870

    (State or other jurisdiction of incorporation)

    ​

    (Commission File Number)

    ​

    (IRS Employer Identification No.)

    ​

    ​

    ​

    4710 Bellaire Boulevard, Suite 210, Bellaire, Texas

        

    77401

    (Address of principal executive offices)

    ​

    (Zip Code)

    ​

    (832) 742-1357

    (Registrant’s Telephone Number, Including Area Code)

    ​

    (Former Name or Former Address, if Changed Since Last Report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

        

    Trading Symbol

        

    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

     

    BPTH

     

    The Nasdaq Capital Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    ​

    Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

    ​

    ​

    ​

    Item 2.02   Results of Operations and Financial Condition.

    ​

    The information in this Current Report on Form 8-K (this “Current Report”) is being furnished pursuant to Item 2.02 of Form 8-K and, according to general instruction B.2. thereunder, the information in this Current Report shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.

    ​

    On November 12, 2021, Bio-Path Holdings, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended September 30, 2021. Additional information is included in the Company’s press release. A copy of the Company’s press release is attached hereto as Exhibit 99.1. The foregoing description of the press release is qualified in its entirety by reference to the attached exhibit.

    ​

    Item 9.01   Financial Statements and Exhibits.

    ​

    (d) Exhibits.

    ​

    Exhibit

        

     

    Number

     

    Description

     

     

     

    99.1

     

    Press Release dated November 12, 2021.

    104

    ​

    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101).

    ​

    ​

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

     

    BIO-PATH HOLDINGS, INC.  

     

     

     

    Dated: November 12, 2021

    By:

    /s/ Peter H. Nielsen

     

     

    Peter H. Nielsen

     

     

    President and Chief Executive Officer

    ​

    ​

    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn